Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy - 29/09/13
Abstract |
Background |
Neoadjuvant chemotherapy (NACT) is used in breast cancer to evaluate the response to treatment. We examined the usefulness of breast magnetic resonance imaging (MRI) in the evaluation of tumor response after NACT.
Methods |
Breast MRIs of 87 women with MRI after NACT were reviewed. The Spearman coefficient was used for estimating the correlation between MRI and pathologic tumor sizes (ypTs).
Results |
The median age was 50 years (range 25 to 83 years). The median MRI size was 1.25 cm (range 0 to 10 cm). The median ypT was 1.20 cm (range 0 to 10.4 cm). The Spearman coefficient between MRI and ypT was .78 (95% confidence interval, .67 to .85; P < .0001). MRI was found to have a positive predictive value of 92% and a negative predictive value of 64% for residual in-breast disease. The sensitivity and specificity of MRI were 86% and 77%, respectively.
Conclusions |
MRI correlates well with the final pathology and can be a useful modality to predict residual disease after NACT and aid in surgical planning.
Le texte complet de cet article est disponible en PDF.Keywords : Breast cancer, Magnetic resonance imaging, Neoadjuvant chemotherapy
Plan
| There is no industry support or conflict of interest to prepare this manuscript |
Vol 206 - N° 4
P. 567-573 - octobre 2013 Retour au numéro
Article précédent
- The use of the Hirsch index in benchmarking hepatic surgery research
- Alessandro Cucchetti, Federico Mazzotti, Sara Pellegrini, Matteo Cescon, Lorenzo Maroni, Giorgio Ercolani, Antonio Daniele Pinna
- Can the use of intraoperative intact parathyroid hormone monitoring be abandoned in patients with hyperparathyroidism?
- Chika Sakimura, Shigeki Minami, Naomi Hayashida, Tatsuya Uga, Naoko Inokuchi, Susumu Eguchi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?